Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Novel blood test helps doctors to manage patients with shortness of breath

01.09.2003


ESC Congress 2003: Hot Line I - Medical Treatment & Heart Failure



We have shown that a simple blood test measuring B-type natriuretic peptide (BNP), a marker of heart failure, greatly helps doctors to manage patients presenting with shortness of breath to the emergency department. Used in conjunction with other clinical information, rapid measurement of BNP reduced hospitalisations, reduced need for intensive care, reduced total treatment time and significantly reduced total treatment cost by 25%.

Shortness of breath is the key symptom of numerous disorders. Cardiac and pulmonary disease are very common and the most important. Unfortunately, the rapid and accurate differentiation of cardiac disease (heart failure) from other causes of shortness of breath remains a clinical challenge, especially in the emergency department.


Heart failure is a major public health problem. Currently, there are more than 15 million patients with heart failure in North America and Europe, with nearly 1.5 million new cases every year. Heart failure is the most frequent cause of hospitalisation in patients more than 65 years of age and these hospitalisations contribute significantly to the enormous cost of the disease. The total direct cost of care for heart failure exceed $38 billion in the United States per year. Therefore, cost-effective management is of paramount importance.

BNP levels have been found to be significantly higher in patients with heart failure as compared with patients whose shortness of breath is due to other causes. Finding a low BNP level in a patient with shortness of breath renders heart failure unlikely and helps the doctor to focus on alternative causes. In contrast, a high BNP level strongly argues for heart failure being the cause. Accordingly, heart failure medication can be initiated immediately. Our study is the first in the world to demonstrate that in fact doctors can do a better job with the rapid measurement of this novel cardiac marker.

The BASEL (B-Type Natriuretic Peptide for Acute Shortness of Breath Evaluation) study was carried out in the emergency department of our inner city University hospital in Basel, Switzerland. It was supported by research grants from the Swiss National Science Foundation, the Swiss Heart Foundation, the Novartis Foundation, the Krokus Foundation, and the University of Basel. We looked at 452 patients who presented with shortness of breath. The usual diagnostic work-up included patient history, physical examination, ECG, chest X-ray and routine blood tests in all patients. In addition, BNP levels were determined in 225 patients (BNP group). The patients did not know whether their work-up included BNP testing or not. Our results show that the use of BNP levels significantly reduced the need for hospital admission (75% versus 85%) or intensive care (15% versus 24%). Total treatment time was 10.5 days in the BNP group as compared with 13.7 days in the clinical group, a significant reduction of 23%. Total cost of treatment was $5,410 in the BNP group as compared with $7,264 in the clinical group, a significant reduction of 26%. Extrapolating this finding to the cost of hospitalisations for heart failure in the United States in 2000 of $30 billion, the use of this simple blood test may save up to $7 billion each year in the United States alone.

Additional studies have been launched to test whether BNP proves also helpful for the evaluation of patients with shortness of breath presenting in doctors office.

Christian Müller, M.D.
University Hospital, Basel
Switzerland

IMPORTANT: This press release accompanies both a presentation and an ESC press conference given at the ESC Congress 2003. Written by the investigator himself/herself, this press release does not necessarily reflect the opinion of the European Society of Cardiology

Camilla Dormer | alfa
Further information:
http://www.escardio.org/vpo

More articles from Health and Medicine:

nachricht Nanoparticles as a Solution against Antibiotic Resistance?
15.12.2017 | Friedrich-Schiller-Universität Jena

nachricht Plasmonic biosensors enable development of new easy-to-use health tests
14.12.2017 | Aalto University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First-of-its-kind chemical oscillator offers new level of molecular control

DNA molecules that follow specific instructions could offer more precise molecular control of synthetic chemical systems, a discovery that opens the door for engineers to create molecular machines with new and complex behaviors.

Researchers have created chemical amplifiers and a chemical oscillator using a systematic method that has the potential to embed sophisticated circuit...

Im Focus: Long-lived storage of a photonic qubit for worldwide teleportation

MPQ scientists achieve long storage times for photonic quantum bits which break the lower bound for direct teleportation in a global quantum network.

Concerning the development of quantum memories for the realization of global quantum networks, scientists of the Quantum Dynamics Division led by Professor...

Im Focus: Electromagnetic water cloak eliminates drag and wake

Detailed calculations show water cloaks are feasible with today's technology

Researchers have developed a water cloaking concept based on electromagnetic forces that could eliminate an object's wake, greatly reducing its drag while...

Im Focus: Scientists channel graphene to understand filtration and ion transport into cells

Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.

To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...

Im Focus: Towards data storage at the single molecule level

The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.

Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

AKL’18: The opportunities and challenges of digitalization in the laser industry

07.12.2017 | Event News

 
Latest News

Engineers program tiny robots to move, think like insects

15.12.2017 | Power and Electrical Engineering

One in 5 materials chemistry papers may be wrong, study suggests

15.12.2017 | Materials Sciences

New antbird species discovered in Peru by LSU ornithologists

15.12.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>